Abstract The “hotness” or “coldness” of the tumors are determined by the information of the
cancer cells themselves, tumor immune characteristics, tumor microenvironment, and …

Background: Immune checkpoint inhibitors (ICIs) have shown encouraging treatment
efficacy for metastatic breast cancer in several clinical trials. However, response only …

Immune checkpoint inhibitors against PD-1/PD-L1 yield improved survival rates of KRAS-
mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy …

Objectives To identify the cooperation of authors, countries, and institutions and explore the
hot topics and future prospects regarding programmed cell death protein 1 (PD-1) and …

Objectives Immune checkpoint inhibitors (ICIs) have brought impressive benefits to cancer
patients, however often accompanied with immune-related adverse events (irAEs). We …

Gene-engineered immune cell therapies have partially transformed cancer treatment, as
exemplified by the use of chimeric antigen receptor (CAR)-T cells in certain hematologic …

The discovery of immune checkpoints has been well known to provide novel clues for
cancer treatments. Immunotherapy against the programmed cell death protein-1 (PD …

BACKGROUND The anti–programmed cell death 1 (anti–PD-1) antibody pembrolizumab is
clinically active against non–small cell lung cancer (NSCLC). In addition to T cells, human …

Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare and distinct subtype of
primary lung cancer characterized by Epstein-Barr virus (EBV) infection. Herein, we reported …

Purpose: Conflicting data have been reported on the prognostic value of PD-L1 protein and
gene expression in breast cancer. Experimental Design: Medline, Embase, Cochrane …